Do analysts recommend IMRN or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, IMRN or MIRA?

Immuron has higher revenue and earnings than MIRA Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.88 -$3.38M N/A N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is IMRN or MIRA more profitable?

Immuron's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A MIRA Pharmaceuticals N/A -140.82% -135.01%

Do analysts prefer GRCE or IMRN?

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 180.37%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GRCE or IMRN?

Immuron has higher revenue and earnings than Grace Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$0.48 N/A Immuron $4.72M 1.88 -$3.38M N/A N/A

Is GRCE or IMRN more profitable?

Immuron's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% Immuron N/A N/A N/A

Do analysts recommend IMRN or CRVO?

CervoMed has a consensus target price of $21.50, indicating a potential upside of 665.12%. Given CervoMed's stronger consensus rating and higher possible upside, analysts clearly believe CervoMed is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has preferable valuation and earnings, IMRN or CRVO?

Immuron has higher revenue and earnings than CervoMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.88 -$3.38M N/A N/A CervoMed $4.01M 9.48 -$26.97M -$3.28 N/A

Is IMRN or CRVO more profitable?

Immuron has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Immuron's return on equity of 0.00% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A CervoMed -672.80% -136.08% -112.62%

Do analysts recommend LTRN or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, LTRN or IMRN?

Immuron has higher revenue and earnings than Lantern Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.45 N/A Immuron $4.72M 1.88 -$3.38M N/A N/A

Is LTRN or IMRN more profitable?

Immuron's return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% Immuron N/A N/A N/A

Do analysts recommend ESLA or IMRN?

Estrella Immunopharma presently has a consensus target price of $8.00, indicating a potential upside of 1,001.93%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Estrella Immunopharma is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ESLA or IMRN?

Immuron has higher revenue and earnings than Estrella Immunopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Immuron $4.72M 1.88 -$3.38M N/A N/A

Is ESLA or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Immuron N/A N/A N/A

Immuron (IMRN) Competitors

$1.10 +0.02 (+1.85%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.10 -0.01 (-0.45%)

As of 08/5/2026 05:51 PM Eastern

Compare

IMRN vs. MIRA, GRCE, CRVO, LTRN, and ESLA

Should you buy Immuron stock or one of its competitors? MarketBeat compares Immuron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuron include MIRA Pharmaceuticals (MIRA), Grace Therapeutics (GRCE), CervoMed (CRVO), Lantern Pharma (LTRN), and Estrella Immunopharma (ESLA).

How does Immuron compare to MIRA Pharmaceuticals?

Immuron (NASDAQ:IMRN) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Immuron has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Immuron has higher revenue and earnings than MIRA Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than Immuron. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for Immuron. Immuron's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Immuron	Neutral
MIRA Pharmaceuticals	Neutral

Immuron's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.1% of Immuron shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MIRA Pharmaceuticals beats Immuron on 6 of the 10 factors compared between the two stocks.

How does Immuron compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 180.37%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Grace Therapeutics had 4 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Grace Therapeutics and 0 mentions for Immuron. Grace Therapeutics' average media sentiment score of 0.50 beat Immuron's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Immuron	Neutral

Immuron's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
Immuron	N/A	N/A	N/A

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Immuron has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Immuron has higher revenue and earnings than Grace Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A

Summary

Grace Therapeutics beats Immuron on 7 of the 12 factors compared between the two stocks.

How does Immuron compare to CervoMed?

Immuron (NASDAQ:IMRN) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

CervoMed has a consensus target price of $21.50, indicating a potential upside of 665.12%. Given CervoMed's stronger consensus rating and higher possible upside, analysts clearly believe CervoMed is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

0.1% of Immuron shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immuron has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, meaning that its share price is 163% less volatile than the broader market.

Immuron has higher revenue and earnings than CervoMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A
CervoMed	$4.01M	9.48	-$26.97M	-$3.28	N/A

In the previous week, CervoMed had 4 more articles in the media than Immuron. MarketBeat recorded 4 mentions for CervoMed and 0 mentions for Immuron. CervoMed's average media sentiment score of 1.00 beat Immuron's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuron	Neutral
CervoMed	Positive

Immuron has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Immuron's return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
CervoMed	-672.80%	-136.08%	-112.62%

Summary

CervoMed beats Immuron on 8 of the 14 factors compared between the two stocks.

How does Immuron compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Immuron's return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
Immuron	N/A	N/A	N/A

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immuron has higher revenue and earnings than Lantern Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A

Lantern Pharma has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Immuron has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lantern Pharma had 4 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Lantern Pharma and 0 mentions for Immuron. Lantern Pharma's average media sentiment score of 0.33 beat Immuron's score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Immuron	Neutral

Summary

Lantern Pharma beats Immuron on 5 of the 9 factors compared between the two stocks.

How does Immuron compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Estrella Immunopharma's average media sentiment score of 0.00 equaled Immuron'saverage media sentiment score.

Company	Overall Sentiment
Estrella Immunopharma	Neutral
Immuron	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Immuron	N/A	N/A	N/A

Immuron has higher revenue and earnings than Estrella Immunopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A

Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Immuron has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Estrella Immunopharma presently has a consensus target price of $8.00, indicating a potential upside of 1,001.93%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Estrella Immunopharma is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Immuron beats Estrella Immunopharma on 5 of the 9 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.72M	$3.57B	$6.87B	$12.98B
Dividend Yield	N/A	3.76%	2.60%	9.79%
P/E Ratio	N/A	7.68	280.34	25.27
Price / Sales	1.88	1,307.74	603.95	94.35
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	1.41	17.16	12.97	6.09
Net Income	-$3.38M	-$12.52M	$3.49B	$347.95M
7 Day Performance	-0.90%	2.34%	2.42%	3.11%
1 Month Performance	-1.79%	-5.11%	-2.87%	-2.99%
1 Year Performance	-33.89%	52.15%	75.29%	20.51%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.1621 of 5 stars	$1.10 +1.9%	N/A	-34.7%	$8.72M	$4.72M	N/A	N/A
MIRA MIRA Pharmaceuticals	0.2554 of 5 stars	$0.84 +0.4%	N/A	-57.0%	$35.42M	N/A	N/A	2
GRCE Grace Therapeutics	2.124 of 5 stars	$2.08 -7.6%	$6.00 +188.5%	-27.7%	$33.84M	N/A	N/A	N/A	Upcoming Earnings Analyst Upgrade Gap Down High Trading Volume
CRVO CervoMed	3.4058 of 5 stars	$2.48 -3.1%	$21.50 +766.9%	-72.0%	$33.55M	$4.01M	N/A	4	News Coverage
LTRN Lantern Pharma	0.7155 of 5 stars	$2.57 -1.2%	N/A	-46.2%	$32.79M	N/A	N/A	20	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. MIRA, GRCE, CRVO, LTRN, and ESLA

How does Immuron compare to MIRA Pharmaceuticals?

Summary

How does Immuron compare to Grace Therapeutics?

Summary

How does Immuron compare to CervoMed?

Summary

How does Immuron compare to Lantern Pharma?

Summary

How does Immuron compare to Estrella Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. MIRA, GRCE, CRVO, LTRN, and ESLA

How does Immuron compare to MIRA Pharmaceuticals?

Which has more risk & volatility, IMRN or MIRA?

Which has higher earnings & valuation, IMRN or MIRA?

Does the media refer more to IMRN or MIRA?

Is IMRN or MIRA more profitable?

Do analysts recommend IMRN or MIRA?

Do insiders & institutionals have more ownership in IMRN or MIRA?

Summary

How does Immuron compare to Grace Therapeutics?

Do analysts prefer GRCE or IMRN?

Does the media favor GRCE or IMRN?

Is GRCE or IMRN more profitable?

Do institutionals and insiders hold more shares of GRCE or IMRN?

Which has more volatility and risk, GRCE or IMRN?

Which has better earnings & valuation, GRCE or IMRN?

Summary

How does Immuron compare to CervoMed?

Do analysts recommend IMRN or CRVO?

Do institutionals & insiders believe in IMRN or CRVO?

Which has more volatility and risk, IMRN or CRVO?

Which has preferable valuation and earnings, IMRN or CRVO?

Does the media refer more to IMRN or CRVO?

Is IMRN or CRVO more profitable?

Summary

How does Immuron compare to Lantern Pharma?

Is LTRN or IMRN more profitable?

Do insiders & institutionals believe in LTRN or IMRN?

Which has higher valuation & earnings, LTRN or IMRN?

Which has more risk & volatility, LTRN or IMRN?

Do analysts recommend LTRN or IMRN?

Does the media favor LTRN or IMRN?

Summary

How does Immuron compare to Estrella Immunopharma?

Do institutionals and insiders have more ownership in ESLA or IMRN?

Does the media favor ESLA or IMRN?

Is ESLA or IMRN more profitable?

Which has preferable earnings and valuation, ESLA or IMRN?

Which has more volatility & risk, ESLA or IMRN?

Do analysts recommend ESLA or IMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools